BLINCYTO 35/38.5 mcg
- Name: BLINCYTO
- Generic Name: Blinatumomab
- Strength: 35 mcg | 38.5 Single-Dose Vial
- Manufactured : Amgen Inc
Medical Uses
Blincyto contains Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. Blincyto uses are:
- B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1%.
- Relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).
Note: – Blincyto is an FDA approved drug.
Warning & Precautions
- Assess patients with blinatumomab injection for signs and symptoms of neurological toxicities. Advise outpatients on Blinatumomab to contact their health specialist if they develop signs/symptoms of neurological toxicities.
- Monitor patients with Blincyto doses for signs and symptoms of infection and treat appropriately.
- Assess laboratory parameters (including, but not limited to, WBC count and absolute neutrophil count) during blinatumomab infusion. Interrupt this medication if prolonged neutropenia occurs.
- Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and total blood bilirubin before the start of and while on Blincyto 35 mcg treatment.
- Assess patients who develop signs of pancreatitis. Management of pancreatitis may need either temporary interruption or discontinuation of Blincyto injection and dexamethasone.
- Healthcare professionals recommend not to have vaccination with live virus vaccines for at least before 2 weeks Blinatumomab 35 mcg treatment, during treatment, and until immune recovery following the last cycle of Blinatumomab.
Documentation & Availability
What documents are required to import Blincyto?
Blincyto (Blinatumomab) injection can be imported by patients or government hospitals on behalf of patients.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is Blincyto available worldwide?
Blincyto (Blinatumomab) injection is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.
Indian Pharma Network (IPN) facilitates the import of critical medications like Blincyto (Blinatumomab) globally, ensuring the named patient supply (NPS). IPN is the facilitator that provides essential support for:
- Availability of Blincyto (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka).
- BLINCYTO Available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc)
- Determining Medicine Price.
- Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
- Ensuring 100% transparency.
Blincyto (Blinatumomab) injection can be made available to patients, doctors, and hospitals in various countries across the globe. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit.
Indian Pharma Network (IPN) can facilitate the supply of Blincyto (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable).
We assure quality and worldwide delivery as per the buyer’s specifications.
Sourcing & Delivery
Indian Pharma Network is proficient in sourcing Blincyto (Blinatumomab) injection from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide in countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
Indian Pharma Network (IPN) is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address. Your health and well-being are our top priorities
Indian Pharma Network helps you to connect with potential distributors, wholesalers, suppliers and dealers of Blincyto in India.
FAQ
What is the Generic Name for the trade name drug Blincyto®?
Blincyto is the trade name for the drug Blinatumomab.
Is Blincyto® approved by the FDA?
Yes, Blincyto® is approved by the FDA. Date of approval: 2014.
What kind of drug is Blincyto?
lincyto is a prescription only medicine, which is used in treating patients with B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1% and relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).
What is the dosage and form of Blincyto® available?
Blincyto® is available as 35 mcg of lyophilized powder in a single-use vial for reconstitution.
What are the ingredients in the medicine Blincyto?
The active ingredient in the vials is Blinatumomab with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, sodium hydroxide preservative-free sterile water for injection.
Is Blincyto chemotherapy?
Blincyto is an immunotherapy medicine because it works with the immune system to find and destroy cancer cells. The drug Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin, and CD3 expressed on the surface of T cells.
How much does Blincyto® cost in India?
You can call or WhatsApp +91-9310090915 or email info@indianpharmanetwork.in to know the Blincyto cost.
What is the latest FDA approval for Blincyto?
On June 14, 2024, the FDA approved Blincyto for use in adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase of chemotherapy. This approval allows its use regardless of measurable residual disease (MRD) status, expanding its applicability to more patients.
How effective is Blincyto in the consolidation phase of B-ALL treatment?
Clinical trials have shown that Blincyto, when added to a multiphase consolidation chemotherapy regimen, significantly improves overall survival rates compared to chemotherapy alone. In the E1910 study, the three-year overall survival was 84.8% for patients receiving Blincyto plus chemotherapy, compared to 69% for those on chemotherapy alone. The five-year overall survival also showed a marked improvement, demonstrating Blincyto’s potential to enhance long-term outcomes.
What makes Blincyto a unique treatment option for B-ALL?
Blincyto is the first and only bispecific T-cell engager (BiTE) therapy approved for the consolidation treatment of B-ALL, regardless of MRD status. This makes it a pioneering option in immuno-oncology, leveraging the body’s immune system to target and destroy cancer cells by bringing T-cells into proximity with cancerous B-cells.
What are the new findings from recent clinical trials regarding Blincyto?
Recent clinical trials, including the E1910 and 20120215 studies, have reaffirmed Blincyto’s efficacy in increasing overall survival and relapse-free survival rates in both adult and pediatric patients with B-ALL. These trials underline the significant impact of Blincyto on long-term patient outcomes, highlighting its role in the consolidation phase of chemotherapy.
Is Blincyto available in Asia?
Blincyto injection is available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
How can I get Blincyto injection?
Indian Pharma Network (IPN) can facilitate the supply of Blincyto (prescription medicine) to locations worldwide while adhering to legal requirements.
How does Blincyto fit into the current treatment landscape for B-ALL?
Blincyto’s approval for use in the consolidation phase represents a shift in the standard of care for B-ALL. By integrating this immunotherapy into earlier phases of treatment, patients may experience deeper remissions and improved survival outcomes, potentially reducing the risk of relapse.
Where is Blincyto available in India?
Blincyto available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
